ZA983169B - Pharmaceutical dosage units - Google Patents

Pharmaceutical dosage units

Info

Publication number
ZA983169B
ZA983169B ZA983169A ZA983169A ZA983169B ZA 983169 B ZA983169 B ZA 983169B ZA 983169 A ZA983169 A ZA 983169A ZA 983169 A ZA983169 A ZA 983169A ZA 983169 B ZA983169 B ZA 983169B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical dosage
dosage units
units
pharmaceutical
dosage
Prior art date
Application number
ZA983169A
Other languages
English (en)
Inventor
Pieter De Haan
Theodora Antonia Maria La Hurk
Adrianus Cornelis Petru Rovers
Jocominus Antonius Ma Zwinkels
Ryoichi Morita
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of ZA983169B publication Critical patent/ZA983169B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA983169A 1997-04-22 1998-04-15 Pharmaceutical dosage units ZA983169B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201180 1997-04-22

Publications (1)

Publication Number Publication Date
ZA983169B true ZA983169B (en) 1998-10-20

Family

ID=8228228

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA983169A ZA983169B (en) 1997-04-22 1998-04-15 Pharmaceutical dosage units

Country Status (26)

Country Link
US (6) US6399594B2 (no)
EP (1) EP0975348B1 (no)
JP (1) JPH10316573A (no)
KR (1) KR100580855B1 (no)
CN (2) CN1146424C (no)
AR (1) AR012480A1 (no)
AT (1) ATE281836T1 (no)
AU (1) AU742037B2 (no)
BR (1) BR9809268A (no)
CA (1) CA2288070A1 (no)
DE (1) DE69827484T2 (no)
DK (1) DK0975348T3 (no)
ES (1) ES2232949T3 (no)
HK (1) HK1023508A1 (no)
HU (1) HUP0001780A3 (no)
ID (1) ID22763A (no)
IL (1) IL123984A (no)
NO (1) NO995127L (no)
NZ (1) NZ338028A (no)
PL (1) PL190227B1 (no)
PT (1) PT975348E (no)
RU (1) RU2207133C2 (no)
TR (1) TR199902530T2 (no)
TW (1) TW570798B (no)
WO (1) WO1998047517A1 (no)
ZA (1) ZA983169B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141850A (en) * 1998-10-16 2005-11-20 Akzo Nobel Nv High purity composition comprising (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-3n-20-yn-3-one
US7763276B1 (en) * 1999-02-26 2010-07-27 Shionogi & Co., Ltd. Chewable soft capsules having improved administration properties and process for producing the same
US20040229854A1 (en) * 2000-11-28 2004-11-18 Pieter Haan De Immediate release dosage form for HRT
KR100979877B1 (ko) * 2001-09-28 2010-09-02 뉴트라슈틱스 인코포레이티드 생물학적 성분의 전달 시스템
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
GB0125061D0 (en) * 2001-10-18 2001-12-12 Norton Healthcare Ltd Pharmaceutical composition
TW200418525A (en) * 2002-11-20 2004-10-01 Akzo Nobel Nv Coated pharmaceutical tablets containing Tibolone
CN1324041C (zh) * 2003-04-01 2007-07-04 上海迪赛诺医药科技开发有限公司 替勃龙晶型i的制备方法
CA2523883C (en) * 2003-04-29 2012-01-03 Akzo Nobel N.V. Antisolvent solidification process
ES2243919T3 (es) * 2003-05-23 2005-12-01 Akzo Nobel N.V. Formulacion solida farmaceutica que contiene tibolona.
WO2005105278A2 (en) * 2004-05-05 2005-11-10 Akzo Nobel N.V. Antisolvent emulsion solidification process
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
WO2005120517A1 (en) * 2004-06-07 2005-12-22 Strides Arcolab Limited Stable liquid suspension formulation comprising synthetic steroids and process for producing the same
CZ300465B6 (cs) * 2007-07-25 2009-05-27 Zentiva, A. S. Zpusob výroby komprimované farmaceutické formulace s obsahem tibolonu
CN102085193B (zh) * 2009-12-08 2013-11-06 北京以岭生物工程技术有限公司 一种替勃龙口腔崩解片及其制备方法
CN104345098B (zh) * 2013-08-05 2016-04-13 华润紫竹药业有限公司 一种测定替勃龙片剂中抗氧剂含量的方法
BR112018072371B1 (pt) 2016-05-04 2024-04-30 Novalon S.A. Uso de um açúcar-álcool, composição farmacêutica, método para preparar uma forma de dosagem sólida compreendendo tibolona e uso de uma composição farmacêutica

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
CH676470A5 (no) * 1988-02-03 1991-01-31 Nestle Sa
IE63051B1 (en) 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
AU671706B2 (en) * 1993-03-05 1996-09-05 Akzo N.V. Use of a Pregnane Derivative
ATE227122T1 (de) * 1993-09-03 2002-11-15 Smithkline Beecham Corp Stabilisierte tablettenformulierung
IL115445A (en) * 1994-10-17 1999-08-17 Akzo Nobel Nv Solid pharmaceutical compositions comprising low dosage active ingredient oil and excipient capable of binding water and their preparation

Also Published As

Publication number Publication date
US20010005513A1 (en) 2001-06-28
CA2288070A1 (en) 1998-10-29
US6514958B1 (en) 2003-02-04
NO995127D0 (no) 1999-10-21
PL336658A1 (en) 2000-07-03
PT975348E (pt) 2005-01-31
HK1023508A1 (en) 2000-09-15
US20040142030A1 (en) 2004-07-22
NO995127L (no) 1999-10-21
WO1998047517A1 (en) 1998-10-29
KR20010020163A (ko) 2001-03-15
CN1253503A (zh) 2000-05-17
ES2232949T3 (es) 2005-06-01
IL123984A (en) 2004-09-27
AU8014698A (en) 1998-11-13
TW570798B (en) 2004-01-11
AU742037B2 (en) 2001-12-13
US20030119801A1 (en) 2003-06-26
DK0975348T3 (da) 2005-03-07
US20040142028A1 (en) 2004-07-22
ID22763A (id) 1999-12-09
JPH10316573A (ja) 1998-12-02
DE69827484T2 (de) 2005-03-17
HUP0001780A3 (en) 2001-02-28
DE69827484D1 (de) 2004-12-16
PL190227B1 (pl) 2005-11-30
NZ338028A (en) 2001-10-26
AR012480A1 (es) 2000-10-18
TR199902530T2 (xx) 2000-05-22
US6399594B2 (en) 2002-06-04
HUP0001780A2 (hu) 2000-12-28
EP0975348A1 (en) 2000-02-02
CN1146424C (zh) 2004-04-21
CN1494908A (zh) 2004-05-12
ATE281836T1 (de) 2004-11-15
EP0975348B1 (en) 2004-11-10
RU2207133C2 (ru) 2003-06-27
KR100580855B1 (ko) 2006-05-17
BR9809268A (pt) 2000-06-27
US20040142031A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
ZA987551B (en) Solid pharmaceutical dosage forms
GB9700504D0 (en) Pharmaceutical compounds
ZA982872B (en) Pharmaceutical formulation
GB9706089D0 (en) Pharmaceutical composition
SG76535A1 (en) Pharmaceutical agents
GB9726563D0 (en) Novel pharmaceutical
AU8495998A (en) Improved dosage units
ZA983169B (en) Pharmaceutical dosage units
GB9726566D0 (en) Novel pharmaceutical
EP1003495A4 (en) PHARMACEUTICAL COMPOUNDS
EG23694A (en) Novel pharmaceutical
GB9716244D0 (en) Pharmaceutical compounds
GB9717444D0 (en) Pharmaceutical composition
ZA982073B (en) Pharmaceutical preparation
GB9717428D0 (en) Pharmaceutical composition
GB9709739D0 (en) Pharmaceutical formulation
PL338781A1 (en) Dosage form
GB9700895D0 (en) Pharmaceutical compounds
GB9717770D0 (en) Pharmaceutical composition
GB2321190B (en) Pharmaceutical composition
GB9706376D0 (en) Novel pharmaceutical
GB9712357D0 (en) Pharmaceutical dosage form
IL120172A0 (en) Pharmaceutical dosage form
IL117184A0 (en) Pharmaceutical dosage form
CA80343S (en) Pharmaceutical tablet